The new indications of the antidepressant drug Brintellix of Lingbei pharmaceutical have been supported by CHMP. This drug will soon become the first antidepressant approved in the EU to improve the cognitive function of patients with depression. The new indications are based on the results of the connecting test. The results show that when compared with placebo, vortioxetine and Lilly's antidepressant competitive product duloxetine can better improve various cognitive indexes of patients.
People with severe depression usually report a series of cognitive symptoms, including obvious difficulties in thinking, attention, and memory of new information, which can damage patients' self-confidence and lead to social disharmony. Although cognitive problems have been well recognized in other mental diseases such as schizophrenia, there are few studies on their impact on depression.
Peb zoo siab tias vortioxetine tau txais cov lus pom zoo los ntawm CHMP, tshwj xeeb tshaj yog cov xwm txheej ntawm kev paub tsis meej hauv kev cuam tshuam cov txiaj ntsig kev kho mob ntawm cov neeg mob feem ntau, hais tias Pedersen, tus thawj coj ntawm Lingbei kev tshawb fawb thiab kev loj hlob. Cov ntaub ntawv txhawb nqa peb tau pom hauv kev hais txog kev paub tsis meej ua rau peb ntseeg tias vortioxetine muaj peev xwm pab ntau tus neeg mob kho lawv txoj kev nyuaj siab.
Votexetine has been listed in the United States for only more than a year, and it is gradually lifted in the whole EU. Last September, it was listed in Denmark, Lingbei's hometown. It is reported that this drug is the fastest-growing new antidepressant in the United States in the past three years. This drug is jointly listed by Lingbei and Takeda in the United States.
Qhov no yog xov xwm zoo rau Lingbei vim tias nws xav tau cov tshuaj tshiab los tsim kom muaj qhov cuam tshuam los ntawm kev tas sij hawm ntawm patent ntawm nws cov qub antidepressant Idprem. Yidepulum yog ib qho tshuaj blockbuster nrog kev muag khoom txhua xyoo ntawm ntau txhiab daus las, uas tau cuam tshuam los ntawm kev sib tw ntawm cov tshuaj generic.
Votexetine sold 188 million kroner (27 million) in six EU markets last year, compared with 83 million kroner in the fourth quarter alone, so it still has some ways to catch up with Idem. Although Idprem no longer has a market franchise, it still sold 4.6 billion kroner. The Danish company also has long-acting schizophrenic drug aripiprazole and an alcohol addiction treatment drug nalmefene, which can help vortioxetine increase the company's revenue again.